Tango Therapeutics (NASDAQ:TNGX) Insider Jessica Newcomb Sells 8,200 Shares of Stock

Posted by Stanley Muller on Sep 25th, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Jessica Newcomb sold 8,200 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider directly owned 59,121 shares in the company, valued at $1,431,910.62. The trade was a 12.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Tango Therapeutics Trading Up 0.7%

Tango Therapeutics stock opened at $24.63 on Friday. The firm has a market capitalization of $4.15 billion, a P/E ratio of -28.98 and a beta of 1.12. Tango Therapeutics, Inc. has a 1 year low of $6.69 and a 1 year high of $34.39. The business has a 50-day moving average of $25.27 and a 200-day moving average of $24.61.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Research analysts anticipate that Tango Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Analysts Set New Price Targets

TNGX has been the topic of several analyst reports. Leerink Partners increased their target price on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics in a report on Wednesday, July 15th. They issued an “overweight” rating and a $46.00 price target for the company. Wall Street Zen cut shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Wolfe Research set a $35.00 price objective on Tango Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, Jefferies Financial Group upgraded Tango Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $27.00 to $60.00 in a report on Thursday, June 25th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.46.

Check Out Our Latest Stock Analysis on Tango Therapeutics

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TNGX. Nykredit A S acquired a new stake in shares of Tango Therapeutics during the 2nd quarter worth $26,000. Allworth Financial LP acquired a new position in Tango Therapeutics in the second quarter valued at about $35,000. Global Retirement Partners LLC bought a new stake in Tango Therapeutics during the second quarter worth about $122,000. State of Wyoming bought a new stake in Tango Therapeutics during the first quarter worth about $128,000. Finally, AXQ Capital LP grew its stake in Tango Therapeutics by 50.5% during the fourth quarter. AXQ Capital LP now owns 20,268 shares of the company’s stock worth $180,000 after buying an additional 6,800 shares in the last quarter. 78.99% of the stock is owned by institutional investors and hedge funds.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities. The company uses genetic screening, functional genomics and drug-discovery technologies to identify cancer-specific dependencies that may be addressed with targeted therapies.

Tango’s research activities center on precision oncology and immuno-oncology, including programs designed to selectively eliminate tumor cells or improve the ability of the immune system to recognize and attack cancer.